Background: Steroid receptor coactivator-3 (SRC-3) is frequently overexpressed in human urinary bladder cancer. Results: SRC-3 promotes urinary bladder cancer (UBC) cells proliferation through coactivating HIF1␣ and up-regulating the expression of genes involved in the glycolytic pathway. Conclusion: SRC-3 plays an important role in UBC development through enhancing glycolysis. Significance: Targeting SRC-3 or enzymes in glycolytic pathway could be an attractive approach in UBC therapy.
The dysregulated metabolic pathway is one of the hallmarks of cancer (1, 2) . As one of them, enhanced glycolysis has been known as the Warburg effect for almost a century (1) (2) (3) . Cancers are composed of a highly proliferative cell population group. In addition to higher energy demand, cancer cell proliferation requires a wide variety of biomolecules and glucose serving as an important precursor for biosynthesis of those molecules, including nucleic acids and lipids. Up-regulated expression of glucose transporters and enzymes in the glycolytic pathway combined with decelerated tricarboxylic acid cycle, and elevated levels of lactate were often observed in cancer cells.
Hypoxia inducible factor 1␣ (HIF1␣) 3 is one of the master regulators of glycolysis. Under normoxic conditions, HIF1␣ is ubiquitinated by the von Hippel-Lindau protein and degraded through the proteasomal pathway. However, under hypoxic conditions the interaction between HIF1␣ and von Hippel-Lindau is interrupted, and consequently, the HIF1␣ protein is not degraded. The stabilized HIF1␣ dimerizes with HIF1␤ and binds to hypoxia-responsive elements (HREs) in promoter regions of HIF1␣ target genes. Glycolytic enzymes HK2, PGK1, and LDHA are all up-regulated HIF1␣ target genes. Due to consistent low oxygen availability to most solid cancer tissues, these glycolytic enzymes were continuously up-regulated in cancer cells (4 -7) . Therefore, specifically targeting the HIF1␣mediated metabolic pathway in cancer cells has been postulated as a valuable therapeutic strategy (8 -10) .
Urinary bladder cancer (UBC) is one of the most common cancers worldwide (11) . The incidence of UBC has been increasing steadily. In the developed countries, UBC takes the fourth leading incidence among cancers in men. However, the annual expense on UBC per patient ranks first among all cancers (12) . Identification of gene mutations (FGFR3 and p53) and chromosome alterations (gain of 9p and 9q) in UBC specimens has shed some light on understanding UBC development (13, 14) . But lacking specific molecular mechanisms underlying the cancer development including initiation, promotion, and progression of UBC hampered the successful treatment of UBC patients.
The steroid receptor coactivator-3 (SRC-3) was originally identified as an amplified gene on chromosome 20q in 30 -60% of human breast cancer specimens (15) . Multiple lines of evidence indicate that overexpression of SRC-3 is a common event in cancers derived from steroid-targeted tissues such as breast, prostate, and ovary (16) . Specific ovrerexpression of SRC-3 in mammary epithelial cells induces breast cancer in mice; therefore SRC-3 has been defined as a bona fide oncogene (17) . However, up-regulated expression of SRC-3 had also been found in cancers derived from non-steroid targeted tissues including the lung, liver, and bladder (18 -20) . In addition, analyses of a cohort of 163 human UBC found that 7.0% of the specimens contain SRC-3 gene amplification and 32.5% show overexpression of the SRC-3 protein (20) . Immunohistochemistry analyses showed that SRC-3 overexpression in UBC specimens was not correlated with estrogen receptor, androgen receptor, and progesterone receptor, suggesting SRC-3 may function through mechanisms other than the steroid receptor coactivator (20) . However, the exact role of SRC-3 in UBC remains unclear.
In this study, we first found that overexpression of SRC-3 is correlated with elevated levels of HIF1␣ target genes in human UBC samples. We further demonstrated that overexpressed SRC-3 in UBC cells not only interacts with HIF1␣ directly but also enhances the expression of HIF1␣ target genes. Finally, we proved that SRC-3 expression is essential for hypoxia-induced glycolysis and tumorigenesis of UBC.
EXPERIMENTAL PROCEDURES
Tissue Samples, Cell Lines, Plasmids, and Reagents-The tumor and adjacent normal tissue samples were obtained from UBC patients in Drum Tower Hospital at Nanjing University Medical School, using appropriate informed consent obtained after institutional review board approval. Human UBC cell lines, including T24, 5637, BIU87, and SCaBER, were purchased from the Cell Bank of Type Culture Collection of Chinese Academy of Sciences (Shanghai, China). Cells were cultured in RPMI1640 medium containing 10% FBS (Hyclone). SRC-3 expression plasmid and shSRC-3 (targeting sequence 5Ј-AACACTGCACTAGGATTATTG-3Ј) plasmid were gifts from Dr. Chundong Yu (19) . HRE-Luc was a kind gift from Dr. Inna Serganova (21) . PGK1-Luc plasmid was generated from human genomic DNA by PCR using primers: forward, 5Ј-GAAGATCTTCACGGGTAACAGGACTACAGGT-3Ј; and reverse, 5Ј-CCCAAGCTTGGGAGAGAGGTCGGTGATTC-GGT-3Ј. To generate the HRE deletion PGK1-Luc plasmid (⌬HRE-PGK1-Luc), we used primers: A2, 5Ј-AGGGTACTAGTCCGCGA-ACCGCAA-3Ј; and B1, 5Ј-GGTTCGCGGACTAGTACCCTCGC-AGA-3Ј. Puromycin, neomycin, MTT, 2-deoxyglucose (DG), sodium oxamate, and deferoxamine (DFO) were purchased from Sigma. 2-DG and sodium oxamate were added into media in 12.5 mg/ml and 80 mM to decrease cancer cell glycolysis.
Generation of Stable SRC-3 Knockdown and Overexpression Cells, Cell Proliferation, and Soft Agar Assays-To generate stable SRC-3 knockdown and mock cells, T24 and 5637 cells were transfected with pSUPER-shSRC-3 and pSUPER-shGFP plasmids, respectively, followed by selection of 1 g/ml of puromycin for 10 days. The clones with SRC-3 overexpression were obtained by transfection of SRC-3 expression plasmid, followed by selection of 800 g/ml of neomycin for 21 days. Western blotting was performed to determine knockdown and overexpression efficiency. Then, cell proliferation of SRC-3 knockdown cells and mock cells were measured by MTT assay. Briefly, 1,000 cells per well were seeded into 96-well plates, followed by MTT assay. UBC cell lines were transfected with 50 nM siRNA to HK2 (5Ј-CACGATGAAATTGAACCT-GGTtt-3Ј), LDHA (5Ј-TTGTTGATGTCATCGAAAGtt-3Ј), and HIF1␣ (5Ј-UGUAGUAGCUGCAU GAUCGTtt-3Ј) at 40 to 60% confluence using Lipofectamine 2000 (Invitrogen). The soft agar assays were carried out as previously described (22) . 1,000 cells were suspended as a single-cell suspension in 0.35% agarose in RPMI1640 containing 10% FBS on 0.6% agarose in the same media in 6-well plates. After 21 days incubation, colonies were stained overnight with 0.5 mg/ml of p-iodonitrotetrazolium violet (Sigma). Colonies Ͼ100 m in diameter were counted.
Quantitative RT-PCR-SYBR Green-based real-time reverse transcription-PCR (RT-PCR) was done using an ABI PlusOne PCR instrument. Total RNAs were isolated using TRIzol (Invitrogen) and reverse transcription was performed using gDNA Erase and PrimeScript RT reagent kits (TAKARA Biotechnology, Dalian, China). For real-time PCR, cDNA reversed from 1 g of total RNA was used. Primer sequences are shown below: src-3 (forward, 5Ј-GGGACTAAGCAACAGGTGTTT-3Ј; reverse, 5Ј-TTTGGCCCACCCATACTTGAG-3Ј); glut1 (forward, 5Ј-GATTGGCTCCTTCTCTGTGG-3Ј; reverse, 5Ј-TCAAAGGACTTGCCCAGTTT-3Ј); hk2 (forward, 5Ј-GAG-CCACCACTCACCCTACT-3Ј; reverse, 5Ј-CCAGGCATTC-GGCAATGTG-3Ј); pgk1 (forward, 5Ј-CATACCTGCTGGCT-GGATGG-3Ј; reverse, 5Ј-CCCACAGGACCATTCCACAC-3Ј); pgm (forward, 5Ј-AGCATTCCGTATTTCCAGCAG-3Ј; reverse, 5Ј-GCCAGTTGGGGTCTCATACAAA-3Ј); ldha (forward, 5Ј-AAGCGGTTGCAATCTGGATTCAG-3Ј; reverse, 5Ј-GGTG-AACTCCCAGCCTTTCC-3Ј); mct4 (forward, 5Ј-CAGTTCG-AGGTGCTCATGG-3Ј; reverse, 5Ј-ATGTAGACGTGGGTC-GCATC-3Ј); ␤-actin (forward, 5Ј-AGCGAGCATCCCCCAA-AGTT-3Ј; reverse, 5Ј-GGGCACGAAGGCTCATCATT-3Ј).
Immunoprecipitation, GST Pull-down, and Western Blotting Assays-Immunoprecipitation assay was described previously (23) . Briefly, transfected cells were lysed in lysis buffer (20 mM Tris-HCl, pH 8.0, 125 mM NaCl, 0.5% Nonidet P-40, 2 mM EDTA, 0.2 mM NaF, 0.2 mM Na 3 VO 4 , protease inhibitor mixture) for 30 min, followed by centrifugation at 12,000 ϫ g for 20 min at 4°C to remove debris. The lysates were incubated with 1.0 g of anti-FLAG (Sigma) antibody for 16 h at 4°C, followed by precipitation of protein A/G-agarose beads. As for GST pulldown, bacterial GST expression vector with SRC-3 domains (bHLH/PAS, S/T, RID, CID, and HAT) were transformed into Escherichia coli BL21(DE3), and the induced fusion protein was expression by 0.5 mM isopropyl 1-thio-␤-D-galactopyranoside at 30°C. After bacteria were split under the ultrasonic method, GST fusion proteins were purified and added to HEK293T cell lysate with overexpression of SREBP-1c N-terminal for the protein-protein interaction incubation. 20 g of whole protein extract were fractionated by PAGE and transferred to a polyvinylidene difluoride (PVDF) membrane, probed overnight with the antibodies against SRC-3 (BD Biosciences and Cell Signaling), Bcl-2, LDHA, HIF1␣ (Bioworld, China), HA, Cyclin D1, and PCNA (Santa Cruz, CA), and Glut1 (Proteintech, IL). ␤-Actin antibody (Abmax, China) was used as a loading control. The Western blot was visualized using the enhanced chemiluminescence kit (Pierce).
Luciferase Assay-1 ϫ 10 5 293T or T24 cells were transfected using Lipofectamine 2000 with 0.2 g of the following plasmids: HRE-Luc, PGK1-Luc, ⌬PGK1-Luc, pCMV-3xFLAG-SRC-3, and pCS2-4HA-HIF1␣. Renilla luciferase plasmid was co-transfected as a transfection efficiency control. 24 h later, cells were harvested and luciferase activity was determined using the Dual-Luciferase Reporter Assay system (Promega). 100 M DFO was added into medium 24 h before the luciferase reporter assay.
Chromatin Immunoprecipitation (ChIP) Assay-ChIP assay was performed as previously described (24) . In brief, the UBC cells were treated with either normoxia (21% O 2 ) or hypoxia (1% O 2 ) for 24 h and chromatin was immunoprecipitated using anti-HIF1␣ (Novus Biologicals), anti-SRC-3 (C-20; Santa Cruz Biotechnology Inc.) antibodies, or nonspecific IgG (Santa Cruz). ChIP DNA were purified and amplified by PCR with specific primers for the HRE regions in the promoters of pgk1 and glut1 genes. The PCR products were separated on 1.0% agarose gel and visualized under UV light. Primers used for the ChIP assay were: glut1 (forward, 5Ј-CTGACTCAGCAAAAC-CTTTCCT-3Ј; reverse, 5Ј-AGGTGCCAGGCGGATGCT-GGA-3Ј) and pgk1 (forward, 5Ј-TAAGTCGGGAAGGTTCC-TTG-3Ј; reverse, 5Ј-GGCTTGCAGAATGCGGAACA-3Ј). Bands were quantified by using ImageJ software (NIH, Bethesda, MD).
Glucose, Lactate, Media pH, and ATP Production Measurements-1 ϫ 10 5 cells were incubated into a 35-mm dish, the cells were either treated with hypoxic (1% O 2 ) or normoxic (21% O 2 ) conditions for 36 h. The medium was collected by centrifugation to remove the cells, and glucose consumption was measured using the Glucose (HK) Assay Kit (Sigma). Lactate levels and pH values in the culture media were measured using the Lactate Assay kit (BioVision) and pH meter. To determine ATP levels, UBC were trypsinized and washed by Dulbec-co's phosphate-buffered saline three times at 4°C and intracellular ATP was assessed using an ATP bioluminescence assay kit (ZhongkeLiangma Bioengineering, China), per the manufacturer's instructions.
Immunohistochemistry-Twenty human UBC tissues were fixed in 4% paraformaldehyde and embedded in paraffin. Sections (5-m thick) were stained with antibodies against SRC-3 (1:800; BD Biosciences) and Glut1 (1:3000; H-43, Santa Cruz) in accordance with the previously described procedure (25) . Nuclear SRC-3 and membrane/cytoplasmic Glut1 expression were quantified using a 10-value intensity score (0 -9) and the percentage (0 -100%) of the extent of reactivity by two pathologists. The whole field in each slide was examined for final quantification. An immunohistochemical expression score was obtained by multiplying the intensity and reactivity extension values, and these expression scores were used to determine expression levels.
Tumor Xenograft-All animal experiments were approved by the Animal Care and Use Committee of the Model Animal Research Center, Nanjing University, China. The cells were resuspended in 50% Matrigel (BD Biosciences) in PBS (1 ϫ 10 7 cells/ml). Athymic mice (6-week-old; Model Animal Research Center) were injected subcutaneously with 200 l of shSRC-3 or shCTRL T24 cells on the flank. Tumor size was measured every 7 days using a caliper and calculated using the formula: volume ϭ (L ϫ W 2 )/2, in which L is the widest diameter of the tumor and W is the diameter perpendicular to L. At the end point, the tumors were harvested for weight.
Statistics Analysis-SPSS software (version 17.0) was used for statistical analysis. Student's t test (two-tailed) or Mann-Whitney U tests were performed as appropriate to compare the intergroup. p Ͻ 0.05 would be considered statistically significant.
RESULTS

Overexpression of SRC-3 in UBC Cells Enhances Aerobic
Glycolysis-To determine the roles of SRC-3 in the development of bladder cancer, we first analyzed SRC-3 expression levels in a panel of human UBC cell lines, and 11 human UBC specimens with their adjacent normal bladder tissues. As shown in Fig. 1A , various levels of SRC-3 were readily detectable in all four tested human UBC cell lines. Compared to that in the adjacent normal bladder tissues, SRC-3 protein levels were much higher in 63.6% (7/11) of UBC specimens. To test whether SRC-3 is overexpressed in UBC samples at the mRNA level, we analyzed a public GEO profile GSE3167 dataset (26) , showing that src-3 is significantly increased in tumor samples ( Fig. 1B) . Moreover, in nine pairs of UBC samples, in which we tested SRC-3 protein levels, we found that SRC-3 is overexpressed in 5 of 9 samples at the mRNA level by qRT-PCR ( Fig.  1B) , which is correlated with its protein levels in UBC samples (Fig. 1A ). Next, we transfected a plasmid overexpressing SRC-3 to BIU87 UBC cells, which have relatively lower SRC-3 expression, and found that, compared to mock cells (CTRL), both stable transfectants (#1 and #2) not only gained a higher proliferative capacity (Fig. 1, C and D) , but also formed more colonies (Ͼ2-fold) in soft agar assays (Fig. 1E ). Western blots showed that two proliferation markers, PCNA and Cyclin D1, were increased in both stable transfectants ( Fig. 1D) . Consistently, the knockdown of SRC-3 in T24 and 5637 cells decreased both bladder cancer cell proliferation, and colony formation ability in soft agar ( Fig. 1, F, I and H, K) . Moreover, the protein levels of PCNA and Cyclin D1 were down-regulated in SRC-3 knock-down stable cell lines (Fig. 1, G and J) . These data suggest that SRC-3 overexpression may confer a growth advantage to bladder cancer cells.
Metabolic pathways in cancer cells are usually reprogrammed favoring glycolysis to provide a source of substrates for the synthesis of amino acid, lipids, and nucleic acids that are essential for proliferation (2) . We next investigated whether the SRC-3 expression level change would affect glucose metabolism in these cells. Under normoxic condition, overexpression of SRC-3 significantly increased glucose consumption and lactate production in BIU87 cells ( Fig. 2A ). In addition, hypoxia induced a higher glycolytic rate in all cells, as expected. Notably, SRC-3 overexpression increased both glucose consumption and lactate production further, compared with control cells (p Ͻ 0.05, Fig. 2A ). Furthermore, we observed that overexpression of SRC-3 also resulted in elevated mRNA expression levels of the glycolytic pathway-related genes, including glut1, hk2, pgk1, pgm, ldha, and mct4, under both normoxic and hypoxic conditions (Fig. 2B) . For example, the Glut1 mRNA transcript increased 1.8-fold in SRC-3 #1 cells and 1.6-fold in SRC-3 #2 cells under normoxia conditions; whereas the increases under hypoxia conditions were 2.9-fold in SRC-3 #1 cells and 3.5-fold in SRC-3 #2 cells, respectively, compared with control cells. Data from Western blot analyses further confirmed the induction of Glut1 and LDHA protein levels in SRC-3 transfectants (Fig. 2C) .
SRC-3 Deficiency Impairs Glycolysis in Bladder Cancer Cells under Hypoxic Conditions-To confirm whether SRC-3 is essentially required for glycolysis in UBC cells, we tested it in stable SRC-3-knockdown cells (shSRC-3) and control shRNAtransduced mock cells (shCTRL) in T24 and 5637 cells. Under hypoxic conditions, knockdown of SRC-3 decreased glucose consumption (by 49.8 and 20.5% in T24 and 5637, respectively), lactate production (by 36.1 and 24.3% in T24 and 5637, respectively), and the intracellular ATP level (by 38.4 and 34.3% in T24 and 5637, respectively) as well as increased the pH value of culture medium (by 4.4 and 2.1% in T24 and 5637, respectively), compared to parental cells. However, no significant changes were observed between knockdown cells and parental cells under normoxic conditions (Fig. 3, A and B) . We also assessed the expression levels of glycolytic genes in shSRC-3 and sh-CTRL T24 cells under both normoxic and hypoxic conditions. Consistently, SRC-3 knockdown significantly suppressed mRNA levels of glut1, hk2, pgk1, pgm, ldha, and mct4 genes under hypoxia conditions (Fig. 3C) . However, the inhibitory effects by depletion of SRC-3 were minimal under normoxia (Fig. 3C ). Western blotting confirmed that down-regulation of Glut1 and LDHA proteins in the shSRC-3 cells was only detectable under hypoxia (Fig. 3D) . These data indicate that SRC-3 is required for glycolysis of cancer cells only under hypoxic conditions.
Suppression of SRC-3 Inhibits Tumorigenicity in Nude Mice-We further evaluated the tumorigenicity of SRC-3 knockdown cells in nude mice. shSRC-3 and shCTRL cells were subcutaneously inoculated on the flanks of animals. Tumor size was measured weekly over 7 weeks for the tumor growth study. Calculated tumor volume over time was plotted (Fig. 4A ). shCTRL cells exhibited significantly faster growth starting at 3 weeks post-tumor cell injection, compared with the shSRC-3 cells (p Ͻ 0.05). At the end point of the experiment, the average tumor weight of the shCTRL xenografts was 70-fold higher than that of the shSRC-3 xenografts (Fig. 4B ). Decreased protein expression levels of SRC-3, PCNA (proliferation marker), and LDHA in shSRC-3 xenografts were detected by Western blot (Fig. 4C ). In summary, SRC-3 plays an essential role in UBC tumor cell proliferation, metabolism, and tumorigenicity through regulating the glycolytic pathway.
SRC-3 Coactivates HIF1␣ Transcriptional Activity in UBC-Because HIF1␣ is a master transcription factor for glycolysis, we explored whether SRC-3 functions as a HIF1␣ coactivator. The co-immunoprecipitation assay demonstrated that SRC-3 could interact with HIF1␣ under normoxic conditions, but more HIF1␣⅐SRC-3 protein complex was detected under hypoxic conditions, probably due to stabilization of HIF1␣ ( Fig.  5A ). Furthermore, a GST pull-down assay identified that SRC-3 directly interacts with HIF1␣ through the N-terminal bHLH/ PAS domain in vitro (Fig. 5, B and C) . DFO, which inhibits the enzymatic activity of prolyl hydroxylases, was used to stabilize HIF1␣ under normoxic conditions (27) . The increased HIF1␣ protein level by DFO treatment was confirmed by Western blot analysis (Fig. 5D, inset) . The luciferase reporter assay based on the transcriptional activity of HIF1␣ revealed that DFO treatment or SRC-3 overexpression alone increased HRE-luc reporter activities by 2.2-and 3.6-fold, respectively. Combined SRC-3 overexpression and DFO treatment strikingly increased HIF1␣-dependent transcriptional activity by 19.3-fold, indicating the synergistic regulation of SRC-3 and HIF1␣ (p Ͻ 0.001; Fig. 5D ). In addition, significantly enhanced HIF1␣ transcriptional activities were proportional to the levels of SRC-3 cotransfected with the HIF1␣ expression vector (Fig. 5E ). Next, we tested whether the effect of SRC-3 on HIF1␣ transcription activity was HRE-dependent. Reporters using the pgk1 pro- moter either with the HRE (PGK1-Luc) or without the HRE (⌬PGK1-Luc) were constructed. Loss of the HRE led to a ⌬PGK1-Luc reporter that could not respond to DFO treatment, SRC-3 overexpression (Fig. 5F) , and even HIF1␣ overexpression ( Fig. 5G ), suggesting that HRE is essential in SRC-3-regulated pgk1 gene expression. On the other hand, knockdown of SRC-3 by RNA interference abrogated the HIF1␣ transcriptional activity (Fig. 5H ). Most importantly, the ChIP assay showed that both SRC-3 and HIF1␣ were recruited to the endogenous glut1 promoter and exogenous pgk1 promoter (Fig. 5I) . These data collectively demonstrated that under hypoxic conditions SRC-3 coactivates HIF1␣ through direct protein binding, and enhances the transcriptional activity of HIF1␣ in cancer cells.
Inhibition of the Glycolysis Pathway Suppresses SRC-3-induced
Cell Proliferation-To further determine whether SRC-3 plays a pivotal role in cancer cell proliferation via downstream targets of HIF1␣ in the glycolytic pathway, we knocked down two key glycolytic enzymes, HK2 and LDHA, by siRNA in UBC cells with or without SRC-3 overexpression (Fig. 6A ). For instance, in SRC-3 #1 BIU87 cells, suppression of HK2 and LDHA decreased cancer cell proliferation by 21.7 and 34.4%, respectively (Fig. 6, B and C) . However, in the parental BIU87 cells, knockdown of HK2 and LDHA slightly reduced proliferation of the cells with endogenous SRC-3 expression by only 12.2 and 22.6%, respectively (Fig. 6, B and C) . In addition, treatment with 2-DG (a hexokinase inhibitor) and sodium oxamate (a competitive inhibitor of the LDH enzyme) inhibited cancer cell proliferation by 37.2 and 53.5%, respectively, in the CTRL cells; whereas, in the presence of overexpressed SRC-3, the same treatments reduced cell proliferation remarkably by 50.2 and 60%, respectively (Fig. 6, D and E) . Moreover, we impaired glycolysis by knockdown of HIF1␣, the proliferation was inhibited by 35.0 and 10.1% in BIU87 #1 and CTRL, respectively (Fig.  6, F and G) . Our data indicate that SRC-3 modulates cancer cell proliferation by up-regulating the glycolytic pathway.
SRC-3 Has Positive Correlation with HIF1␣-regulated Genes in the Glycolytic Pathway and Proliferation in Human UBC
Specimens-The correlation between the expression levels of SRC-3 and HIF1␣-regulated glycolytic genes in 20 human UBC samples was also examined. We observed that the level of SRC-3 nuclear staining was positively associated with the level of Glut1 membrane staining. Immunohistochemistry staining of SRC-3 and Glut1 in two representative UBC patients was shown in Fig. 7A ; SRC-3 and Glut1 were not detectable in case 1 and a strong nuclear staining of SRC-3 coincided with a strong membrane staining of Glut1 in case 2. The intensities of SRC-3 nuclear staining and Glut1 membrane staining were quantified ( Fig. 7B ) and high positive correlation between these two factors was identified by Pearson correlation analysis (r ϭ 0.721; p Ͻ 0.001). In addition, 46 human UBC samples from the public GEO profile dataset (GSE3167; 26) were analyzed. SRC-3 was not only positively correlated with two well established HIF1␣ target genes, pgk1 (r ϭ 0.2721, p ϭ 0.0354) and vegfa (r ϭ 0.4666, p ϭ 0.0002), but also with proliferation marker pcna (r ϭ 0.4567; p ϭ 0.0002; Fig. 7C ). Taken together, the correlation between SRC-3 and HIF1␣-regulated glycolytic genes was established in clinical UBC specimens, indicating its role in UBC cell proliferation via HIF1␣ to augment the Warburg effect.
DISCUSSION
Deregulation of glucose metabolism is frequently found in cancer cells and known as one of the 10 hallmarks of cancer (1, 28) . Because HIF1␣ is one of the major transcription factors to up-regulate the expression of glycolytic genes, understanding the mechanism regulating HIF1␣ activity in glycolysis is important for developing more effective and targeted therapies. In this study, we have showed that SRC-3 regulates glucose metabolism through its interaction with HIF1␣ and coactivation of the transcriptional activity of HIF1␣ to facilitate cancer cell growth. Overexpression of SRC-3 increases aerobic glycolysis in BIU87 bladder cancer cells, accompanied with elevated expression of genes in the glycolytic pathway (Fig. 2) . SRC-3 inhibition suppressed glycolysis under hypoxic conditions in T24 and 5637 UBC cells and T24 xenografts ( Figs. 3 and 4) , indicating the role of SRC-3 in reprogramming cancer cell metabolism. Furthermore, correlated overexpression of both SRC-3 and enzymes involved in the glycolytic pathway in human UBC specimens confirms the in vitro results. Altogether, these data provide a mechanism whereby SRC-3 functions as an oncogene by regulating glycolytic metabolism.
SRC-3 was characterized as a coactivator for steroid hormone receptors, such as estrogen receptor, progesterone receptor, and androgen receptor (16, 29 -31) , and overexpression of SRC-3 has been reported in multiple steroid hormone-targeted cancers, including prostate and breast cancers. But none of the samples in a cohort of 163 UBC with amplification and overex- 
SRC-3 Induces Glycolysis through HIF1␣
pression of SRC-3 showed IHC positive staining of androgen receptor or progesterone receptor, nor any correlation between the expression of SRC-3 and estrogen receptor (20) . Multiple lines of evidence from recent reports indicate that SRC-3 may also activate transcription factors such as AP-1 and PEA3 (25, (32) (33) (34) (35) . Very recently, SRC-3 was reported to coactivate the E2F1 transcriptional factor and drive cell cycle proteins in bladder cancer cells (36) . Consistent with these findings, we demonstrated that SRC-3 could also coactivate the HIF1␣ transcription factor and up-regulate genes in the glycolytic pathway. This suggests that SRC-3 is indeed a master coregulator (37) and activates a much wider spectrum of transcription factors than assumed originally. Therefore, amplification and/or overexpression of SRC-3 in cancer cells made this coactivator readily available for activation of multiple transcription factors and orchestrating the expression of genes in different pathways. Considering that the strong nuclear stain-ing of SRC-3 has been reported as a poor prognostic marker for UBC patients (20) , we propose that any strategies specifically targeting SRC-3 could be a promising therapeutic approach in UBC treatment.
HIF1␣ is degraded through the proteasome pathway under normoxic conditions, but stabilized during hypoxia and consequently promotes the transcription of a battery of genes including those in the glycolytic pathway, such as hk2, pgk1, and ldha (38, 39) . Our data revealed that overexpression of SRC-3 coactivates HIF1␣ in UBC cells to induce expression of glycolytic genes under both normoxic and hypoxic conditions (Fig. 2) . However, the loss of SRC-3 affected glycolysis only in hypoxia, but not in normoxia (Fig. 3) . Given that several cofactors, such as CBP and p300, have been implicated in HIF1␣ activation (40 -42) , we postulate that these coactivators may compensate for the effects from SRC-3 depletion in T24 cancer cells under normoxia. A, ectopic SRC-3 protein interacted with HIF1␣ in T24 cells. T24 cells were transiently transfected with FLAGtagged SRC-3. Co-immunoprecipitation (IP) assay was carried out in cells treated under either normoxia or hypoxia conditions. The precipitant by the IgG antibody was used as a negative control. B, schematic representation of five fragments of SRC-3 representing different domains. C, five fragments of SRC-3 were generated in E. coli BL21(DE3) as GST fusion proteins. The purified GST fused proteins were incubated with HEK293T lysate, which contained the ectopic expression of HA-HIF1␣. Western blot (WB) was performed to detect the pulled down HIF1␣ by HA antibody. D-H, luciferase activity assay: D, in the HRE-Luctransfected 293T cells co-transfected with SRC-3 expression plasmid, with or without DFO treatment, ***, p Ͻ 0.001, compared empty vector transfection group; ###, p Ͻ 0.001 compared with the SRC-3 transfection group; E, in HRE-Luc 293T cells with co-transfection of SRC-3 and HIF1␣ expression plasmids with the indicated amount of plasmids, ***, p Ͻ 0.001; F, in the PGK1-reporter 293T cells co-transfected with the SRC-3 expression plasmid, with or without DFO treatment, ***, p Ͻ 0.001, compared with the empty vector transfection group; ###, p Ͻ 0.001, compared with the SRC-3 transfection group; G, in the PGK1-reporter 293T cells with co-transfection of SRC-3 and HIF1␣ expression plasmids. PGK1-Luc, wild type PGK1 reporter; ⌬PGK1-Luc, PGK1 reporter without HRE; followed by transfection with or without HIF1␣. H, in HRE-Luc T24 cells transduced with control (Ϫ) or SRC-3 shRNA (ϩ), with or without HIF1␣ overexpression, ***, p Ͻ 0.001, compared with the empty vector transfection group; ###, p Ͻ 0.001, compared with the group with SRC-3 knockdown and HIF1␣ overexpression. I, presence of HIF1␣ and SRC-3 on the endogenous glut1 promoter and pgk1 promoter from the pgk1-luc reporter detected by the ChIP assay. Parental T24 cells (left panel) and T24 wells transfected with the pgk1-luc reporter plasmid (right) were incubated under normoxia (N) or hypoxia (H), respectively. The band intensity was shown under each blot, which was quantified by ImageJ software. The precipitant by IgG antibody was used as a negative control. RLU, relative light units.
Cancer cells are more addicted to glycolysis, a pathway providing sufficient metabolic intermediates to support anabolic processes in the highly proliferative cancer cells (43, 44) . Therefore, suppression of the intracellular glucose metabolism could be a targeted approach to suppress cancer cell proliferation. Multiple lines of evidence from recent reports revealed this approach is not only reasonable but also feasible. For instance, a specific LDH inhibitor, oxamate, increased sensitivity of breast cancer cells to taxol (45) . Animals treated with 2-DG and Mito-CP, a mitochondria-targeted drug, induced significant inhibition of tumor growth without any significant side effects (10) . More interestingly, tissue-specific knock-out of HK2 in different animal models demonstrated that KRas-driven lung cancer and ErbB2driven breast cancer developments were inhibited (46) . SRC-3 amplification and overexpression have been detected in 7 and 35% of UBC patients, respectively. In the present report, we demonstrated that SRC-3 overexpression increases the glycolytic rate in bladder cancer cells through up-regulating the expression of genes in the glycolytic pathway. In addition, both knockdown and pharmacologic inhibition of HK2 and LDHA suppressed SRC-3 overexpression-induced cell proliferation, suggesting that SRC-3 overexpressing UBC cells are more addicted to the glycolysis pathway. Because systematic deletion of HK2 does not show any significant adverse physiological consequence (46) , targeting any key enzymes in the glycolytic pathway could be an attractive and safe therapeutic approach for solid tumors.
In summary, our data have demonstrated that SRC-3 plays an important role in cell proliferation during tumor progression by enhancing glycolysis through up-regulation of the enzymes in the glycolytic pathway. Whether SRC-3 affects 
